Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin long-term follow-up in treatment-resistant depression after COMP 001 and COMP 003
2020-001348-25Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (4 arms), sponsored by COMPASS Pathways. Primary endpoints: Time to any depression-related event, New antidepressant treatment use and 3 more. Started May 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-001348-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001348-25.